Craig-Hallum lowered the firm’s price target on Accelerate Diagnostics to $1 from $2 and keeps a Hold rating on the shares. As outlined in the preliminary release, Q4 results continued to present challenges for Accelerate, the firm says. Specifically, Beckton Dickinson still has yet to gain momentum, few Pheno systems were placed, consumable sales declined quarter-over-quarter, and the capital position remains tight – even with a $15M equity raise in January. One bright spot in the quarter was the continued progress on Wave, says Craig-Hallum.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXDX:
- Stockholders Beware: Accelerate Diagnostics’ Surge in Authorized Shares Signals Potential Dilution Risk
- Accelerate Diagnostics reports Q4 EPS (89c), consensus (75c)
- Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
- Accelerate Diagnostics (AXDX) Q4 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue